SecurityWMT / Wal-Mart Stores, Inc.
InstitutionBerkshire Hathaway Inc
ManagerWarren Buffett
Shares1,393,513
Value $ 137,610,000
Related 931142CG6 / Wal-mart 5.375% Notes 4/5/17
931142CH4 / Wal-mart 5.875% Notes 4/5/27
931142CZ4 / Wal-mart Stores 3.25% Senior Notes 10/25/20
931142CL5 / Wal-mart Stores 4.25% Senior Notes 4/15/13
931142CJ0 / Wal-mart Stores 5.8% Notes 2/15/18
931142CM3 / Wal-mart Stores 6.2% Senior Notes 4/15/38
931142CK7 / Wal-mart Stores 6.5% Notes 8/15/37
931142CX9 / Wal-mart Stores Inc. 1.50% Senior Notes 10/25/15
931142DA8 / Wal-mart Stores, Inc. 1.625% Senior Notes 04/15/14
931142DC4 / Wal-mart Stores, Inc. 2.80% Senior Notes 04/15/16
931142DD2 / Wal-mart Stores, Inc. 4.25% Senior Notes 04/15/21
931142BT9 / Wal Mart Stores Inc 4.550% Notes 05/01/13
931142BY8 / Wal Mart Stores Inc 4.5% Notes 7/1/2015
931142CY7 / Wal-mart Stores Inc. 5.0% Senior Notes 10/25/40
931142CB7 / Wal Mart Stores Inc 5.25% Notes 9/1/2035
931142DB6 / Wal-mart Stores, Inc. 5.625% Senior Notes 04/15/41
931142AU7 / Wal Mart Stores Inc 6.750% Debentures 10/15/23
931142AS2 / Wal Mart Stores Inc 7.25% Debs 06/01/13
931142BF9 / Wal Mart Stores Inc 7.550% Notes 02/15/30
931142CW1 / Wal-mart Stores Inc. .75% Senior Notes 10/25/13
931142CT8 / Wal-mart Stores Inc Fixed Rate Notes 2.25% 07/08/2015
931142CU5 / Wal-mart Stores Inc Fixed Rt Notes 3.625% 07/08/2020
931142CV3 / Wal-mart Stores Inc Fixed Rt Notes 4.875% 07/08/2040
931142CR2 / Wal Mart Stores Inc Notes 2.875% 04/01/15
931142CN1 / Wal Mart Stores Inc Notes 3% 02/03/14
931142CQ4 / Wal Mart Stores Inc Notes 3.2% 05/15/14
931142CP6 / Wal Mart Stores Inc Notes 4.125% 02/01/19
931142CS0 / Wal Mart Stores Inc Senior Notes 5.625% 04/01/40

Berkshire Hathaway Inc ownership in WMT / Wal-Mart Stores, Inc.

February 14, 2018 - Berkshire Hathaway Inc has filed a 13F-HR form disclosing ownership of 1,393,513 shares of Wal-Mart Stores, Inc. (NYSE:WMT) with total holdings valued at $137,610,000 USD as of December 31, 2017. Berkshire Hathaway Inc had filed a previous 13F-HR on November 14, 2017 disclosing 1,393,513 shares of Wal-Mart Stores, Inc. at a value of $108,889,000 USD. This represents a change in shares of 0.00 percent and a change in value of 26.38 percent during the quarter.

Other investors with positions similar to Berkshire Hathaway Inc include Old Mutual Global Investors (UK) Ltd., Oppenheimer Funds Inc, Prudential Plc, Focused Investors LLC, Td Asset Management Inc, and Stifel Financial Corp.

WAL MART STORES INC has declared a standard industrial code (sic) of 5331 which is the "Variety Stores" industry. Berkshire Hathaway Inc's top industries are "Motor Freight Transportation And Warehousing" (sic 42), "Educational Services" (sic 82), and "Electronic And Other Electrical Equipment And Components, Except Computer Equipment" (sic 36).

Berkshire Hathaway Inc ownership in WMT / Wal-Mart Stores, Inc.

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2017-12-31 13F-HR WAL MART STORES COM 931142103 88.45 1,393,513 0.00 137,610 26.38 0 28,721 26.38
2017-09-30 13F-HR WAL MART STORES COM 931142103 76.91 1,393,513 0.00 108,889 3.25 0 3,428 3.25
2017-06-30 13F-HR WAL MART STORES COM 931142103 73.88 1,393,513 0.00 105,461 4.99 0 5,016 4.99
2017-03-31 13F-HR WAL MART STORES COM 931142103 70.60 1,393,513 0.00 100,445 4.28 0 4,125 4.28
2016-12-31 13F-HR WAL MART STORES COM 931142103 70.62 1,393,513 -89.26 96,320 -89.70 -817,644 -21,546 -2.30
2016-09-30 13F-HR WAL MART STORES COM 931142103 72.57 12,971,574 -67.75 935,510 -68.15 -1,977,883 -23,939 -0.81
2016-06-30 13F-HR WAL MART STORES COM 931142103 70.76 40,226,402 -27.17 2,937,332 -22.36 -1,061,994 216,222 5.72
2016-03-31 13F-HR WAL MART STORES COM 931142103 64.90 55,235,863 -1.69 3,783,104 9.84 -61,613 400,559 11.63
2015-12-31 13F-HR WAL MART STORES COM 931142103 63.07 56,185,293 0.00 3,444,158 -5.46 0 -198,897 -5.46
2015-09-30 13F-HR WAL MART STORES COM 931142103 67.88 56,185,293 -6.96 3,643,055 -14.94 -285,117 -354,957 -8.29
2015-06-30 13F-HR WAL MART STORES COM 931142103 76.59 60,385,293 0.00 4,283,129 -13.76 0 -683,562 -13.76
2015-03-31 13F-HR WAL MART STORES COM 931142103 84.06 60,385,293 0.00 4,966,691 -4.23 0 -219,196 -4.23
2014-12-31 13F-HR WAL MART STORES COM 931142103 81.18 60,385,293 0.00 5,185,887 12.31 0 568,224 12.31
2014-09-30 13F-HR WAL MART STORES COM 931142103 75.77 60,385,293 2.70 4,617,663 4.62 120,325 83,428 1.89
2014-06-30 13F-HR WAL MART STORES COM 931142103 58,797,259 4,413,910

Related SEC Filings

WMT / Wal-Mart Stores, Inc. / Walton Helen R Walton S Robson Walton John T Walton Jim Etal - SCHEDULE 13G AMENDMENT NO. 37 (Passive Investment)

2018-02-09 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 37)*     WALMART INC. (Name of Issuer) Common Stock (Title of Class of Securities) 931142-10-3 (CUSIP Number)     12/31/17     (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1(b)     o Rule 13d-1(c)     ý Rule 13d-1(d)   * The rema

WMT / Wal-Mart Stores, Inc. / Walton Helen R Walton S Robson Walton John T Walton Jim Etal - SCHEDULE 13G AMENDMENT NO. 37 (Passive Investment)

2018-02-09 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 37)*     WALMART INC. (Name of Issuer) Common Stock (Title of Class of Securities) 931142-10-3 (CUSIP Number)     12/31/17     (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1(b)     o Rule 13d-1(c)     ý Rule 13d-1(d)   * The rema

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...



CUSIP: 931142103